Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

The approval and availability of Epioxa, a noninvasive, epithelium-on, oxygen-enriched treatment for keratoconus represents a significant advancement in patient care. Not only does Epioxa provide a ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including Medicare coverage limitations, out-of-pocket costs, and the role of assistance ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...

September 2, 2008 — A gene variant that protects against geographic atrophy has been identified by investigators from several institutions in China and the United States. The variant appears to ...

Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase 2 program. Dosing compares two intravitreal dose levels given every 12 or ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...